Douglas Lane & Associates LLC Has $80.90 Million Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Douglas Lane & Associates LLC has increased its stake in Thermo Fisher Scientific by 6.6% to a total of 199,531 shares, valued at approximately $80.90 million.
• Insiders sold a total of 30,066 shares worth around $14.2 million in the last quarter, indicating a 14.24% decrease in the position of CAO Joseph R. Holmes.
• Wall Street analysts have mixed ratings for Thermo Fisher, with a consensus rating of "Moderate Buy" and a price target ranging from $480 to $592.24.

Douglas Lane & Associates LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 199,531 shares of the medical research company's stock after acquiring an additional 12,333 shares during the period. Thermo Fisher Scientific accounts for approximately 1.2% of Douglas Lane & Associates LLC's investment portfolio, making the stock its 23rd biggest holding. Douglas Lane & Associates LLC owned approximately 0.05% of Thermo Fisher Scientific worth $80,902,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of TMO. Brighton Jones LLC grew its holdings in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC boosted its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after purchasing an additional 461 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 3.0% during the 4th quarter. ProShare Advisors LLC now owns 58,220 shares of the medical research company's stock worth $30,288,000 after purchasing an additional 1,696 shares in the last quarter. Finally, Scientech Research LLC boosted its position in shares of Thermo Fisher Scientific by 68.9% during the 4th quarter. Scientech Research LLC now owns 2,733 shares of the medical research company's stock worth $1,422,000 after purchasing an additional 1,115 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 in the last quarter. Insiders own 0.33% of the company's stock.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. UBS Group raised their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Finally, Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $490.00 to $550.00 in a research report on Thursday. Seventeen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $592.24.

Thermo Fisher Scientific Trading Down 2.4%

NYSE:TMO opened at $479.48 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market cap of $181.06 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 2.62 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77. The firm has a 50-day moving average price of $466.86 and a two-hundred day moving average price of $451.08.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.